Long term shareholders well rewarded as Company pays $2.40 per share in special dividends between 2018 - 2022.
Expanded into Covid-19 testing and within a short period built a substantial business with a 25,000 sq. foot state-of-the art CLIA lab in Garden City, NY.
Acquisition of Nebula Genomics. Plan to leverage Food, Drug and Mass distribution and genomic sequencing in CLIA labs. Significant upside.
Q4 2022
Strong Rev and Earnings growth for FY2021 - Reported Net Rev of $79m vs. $14.5m for FY2020. FY2021 Net Income - $6.3m vs. net loss of $2.1m FY 2020. FY2021 Adj EBITDA $18.1m vs. ($307,000)¹ FY2020.
1. See Appendix A for reconciliation
Announced expansion of CLIA lab to include traditional clinical testing capabilities.
Initiated plans to expand in-house, B2B genomic testing. Formation of ProPhase BioPharma and licensed two potential broad based anti-virals, Equivir (Dietary Supplement) and Equivir G (Rx).
Licensed Linebacker (LB-1 and LB-2) portfolio. Initial goal - develop LB-1 as anti- cancer agent co- therapy targeting PIM kinase receptors, a growth factor
expressed in cancer.
Announced collaboration with G42
Healthcare, a subsidiary of G42, which launched a $10 billion tech fund. Also announced initial agreement to improve genomic sequencing capabilities. ProPhase, G42 Healthcare collaboration to explore creation of advanced genomic sequencing facility in U.S.
Announced two-year collaboration with Dana-Farber Cancer Institute to further the research and development of LB-1.
Announced acquisition of world-wide exclusive rights to the BE-Smart Esophageal Pre-Cancer diagnostic screening
Net Revenue: $122.6m vs. $79.0m 2021. Net Income: $18.5m vs. $6.3m 2021. Adjusted EBITDA: $38.6m vs. $17.1m.¹ 2021 Cash, cash equivalents and marketable equity securities of $17.4 million and working capital of $44.8 million.
Commence dramatic expansion plan for PMI. Building capacity for $60-$80 million of revenues by yearend 2024.
test and related intellectual property assets.
1. See Appendix A for reconciliation
26
Attachments
Original Link
Original Document
Permalink
Disclaimer
ProPhase Labs Inc. published this content on 06 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 November 2023 14:05:50 UTC.
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
PROPHASE LABS, INC. 
